FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Disclosed is a molecule specifically binding ligand-1 protein programmable death (PDL1) and use thereof, for example, as part of a pharmaceutical composition for treating or preventing cancer. Invention also discloses a nucleic acid molecule encoding said PDL1-binding molecule, an expression vector and a host cell for producing a PDL1-binding molecule.
EFFECT: invention provides binding with PDL1 with high affinity and specificity, which leads to blocking PDL1 binding to PD-1.
20 cl, 24 dwg, 7 tbl, 6 ex
| Title |
Year |
Author |
Number |
| FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME |
2014 |
- Govindappa Nagaraj
- Soares Maria Melina
- Sastry Kedarnath
|
RU2662991C2 |
| FUSED IMMUNOMODULATORY PROTEINS AND METHODS FOR PRODUCTION THEREOF |
2014 |
- Govindappa Nagaraj
- Soares Maria Melina
- Sastry Kedarnath
|
RU2698975C2 |
| PD-1 ANTIBODIES AND USE THEREOF |
2016 |
|
RU2722451C1 |
| NANOANTIBODY SPECIFICALLY BINDING MUC1 PROTEIN, METHOD OF MUC1 PROTEIN DETECTION BY NANOANTIBODIES |
2012 |
- Tillib Sergej Vladimirovich
|
RU2493165C1 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN |
2016 |
- Zheng, Yong
- Li, Jing
- Gololobov, Gennady
- Zhang, Xinhua
- Yang, Baotian
- Tang, Zhewei
- Li, Dong
- Xu, Jianqing
- Wang, Zhuozhi
|
RU2757316C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2013 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2599417C2 |
| NANOANTIBODY SPECIFICALLY BINDING CEA PROTEIN, METHOD OF ITS USAGE FOR DETECTION OF THIS PROTEIN |
2012 |
- Tillib Sergej Vladimirovich
|
RU2493166C1 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
- Khuan Khajchun'
|
RU2494107C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
|
RU2406760C2 |
| ANTI-TAT226 ANTIBODIES AND IMMUNOCONJUGATES |
2007 |
- Ljan Vehj-Ting
- Sakanaka Tie
- Vu Jan
|
RU2448980C2 |
